Researchers monitoring the brain activity of a patient with a severe binge-eating problem reported that Eli Lilly's GLP-1 ...

Researchers reported that Eli Lilly’s GLP-1 weight-loss drug appeared to temporarily suppress food-craving signals in the ...

(Reuters) -Telehealth company Mangoceuticals said on Thursday it has partnered with Eli Lilly and Novo Nordisk to sell the ...

The trillion-dollar club has become crowded with mostly tech names riding the AI boom. Eli Lilly might soon join them for a ...

People buying the peptide retatrutide online could suffer from side-effects ranging from nausea to pancreatitis ...

The race to develop the next generation of weight loss drugs has taken an interesting new turn. In recent research, Eli Lilly ...

Novo Nordisk and Eli Lilly deny partnership with Mangoceuticals for weight-loss drugs, causing Mangoceuticals' shares to ...

Mangoceuticals (MGRX) stock climbs as the company partners with Eli Lilly (LLY) and Novo Nordisk (NVO) to offer GLP-1 weight ...

Novo Nordisk and Eli Lilly denied weight-loss drug partnership with Mangoceuticals on Thursday, hours after the telehealth ...

Eli Lilly's next-gen obesity drugs, led by oral orforglipron and triple-acting retatrutide, aim to reshape the fast-growing weight-loss market.

Eli Lilly is well on its way to the trillion-dollar club. The stock price is up 30% so far this year; with a total ...

GLP-1 RAs, particularly semaglutide and tirzepatide, outperform older medications in achieving significant weight loss in adults with and without type 2 diabetes. Semaglutide and tirzepatide met ...